Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 13 - New advances and new horizons in assisted reproduction

Export citation
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Altchek's Diagnosis and Management of Ovarian Disorders
  • Online ISBN: 9781139003254
  • Book DOI: https://doi.org/10.1017/CBO9781139003254
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

1. Birmingham A. Ovulation Drugs: A Guide for Patients. Birmingham, AL: The American Fertility Society; 1990, p 8.
2. Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action – a hypothesis revisited. Fertil Steril. 1984;42(3):331–44.
3. Caglar GS, Asimakopoulos B, Nikolettos N, et al. Recombinant LH in ovarian stimulation. Reprod Biomed Online. 2005;10(6):774–85.
4. Balasch J, Fabregues F. LH in the follicular phase: neither too high nor too low. Reprod Biomed Online. 2006;12(4):406–15.
5. Buhler K, Naether O. A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study. Gynecol Endocrinol. 2011;27(9):650–4.
6. Schriock ED, Jaffe RB. Induction of ovulation with gonadotropin-releasing hormone. Obstet Gynecol Surv. 1986;41(7):414–23.
7. Dodson WC. Role of gonadotropin releasing hormone agonists in ovulation induction. J Reprod Med. 1989;34(1 Suppl):76–80.
8. Moghissi KS. Gonadotropin releasing hormones. Clinical applications in gynecology. J Reprod Med. 1990;35(12):1097–107.
9. Santen RJ, Bourguignon JP. Gonadotropin-releasing hormone: physiological and therapeutic aspects, agonists and antagonists. Horm Res. 1987;28(2–4):88–103.
10. Filicori M, Flamigni C. GnRH agonists and antagonists. Current clinical status. Drugs. 1988;35(1):63–82.
11. Penzias AS, Shamma FN, Gutmann JN, et al. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial. Obstet Gynecol. 1992;79(5 Pt 1):739–42.
12. Davoren JB, Hsueh AJ. Growth hormone increases ovarian levels of immunoreactive somatomedin C/insulin-like growth factor I in vivo. Endocrinology. 1986;118(2):888–90.
13. Allen RE, Palopoli FP, Schumann EL, et al. US Patent 2,914,563. 1959.
14. Ernst S, Hite G, Cantrell JS, et al. Stereochemistry of geometric isomers of clomiphene: a correction of the literature and a reexamination of structure-activity relationships. J Pharm Sci. 1976;65(1):148–50.
15. Edwards RG, Steptoe PC, Purdy JM. Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br J Obstet Gynaecol. 1980;87(9):737–56.
16. Fritz MA, Speroff L. The endocrinology of the menstrual cycle: the interaction of folliculogenesis and neuroendocrine mechanisms. Fertil Steril. 1982;38(5):509–29.
17. Gronow MJ. Ovarian hyperstimulation for successful in vitro fertilization and embryo transfer. Acta Obstet Gynecol Scand Suppl. 1985;131:1–80.
18. Shoham Z, Borenstein R, Lunenfeld B, et al. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles. Clin Endocrinol (Oxf). 1990;33(2):271–8.
19. Stanger JD, Yovich JL. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol. 1985;92(4):385–93.
20. Homburg R, Armar NA, Eshel A, et al. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ. 1988;297(6655):1024–6.
21. Howles CM, Macnamee MC, Edwards RG, et al. Effect of high tonic levels of luteinising hormone on outcome of in-vitro fertilisation. Lancet. 1986;2(8505):521–2.
22. Bateman BG, Kolp LA, Nunley WC Jr, et al. Subclinical pregnancy loss in clomiphene citrate-treated women. Fertil Steril. 1992;57(1):25–7.
23. Induction of ovulation. Ch. 31 in Speroff L, Glass RH, Kas NG (Eds.). Clinical Gynecologic Endocrinology and Infertility, 8th edition. Baltimore, MD: Williams & Wilkins; 2011. p 1293.
24. Lopata A. Concepts in human in vitro fertilization and embryo transfer. Fertil Steril. 1983;40(3):289–301.
25. Marrs RP, Vargyas JM, Shangold GM, et al. The effect of time of initiation of clomiphene citrate on multiple follicle development for human in vitro fertilization and embryo replacement procedures. Fertil Steril. 1984;41(5):682–5.
26. Quigley MM, Maklad NF, Wolf DP. Comparison of two clomiphene citrate dosage regimens for follicular recruitment in an in vitro fertilization program. Fertil Steril. 1983;40(2):178–82.
27. Quigley MM, Schmidt CL, Beauchamp PJ, et al. Enhanced follicular recruitment in an in vitro fertilization program: clomiphene alone versus a clomiphene/human menopausal gonadotropin combination. Fertil Steril. 1984;42(1):25–33.
28. Diamond MP, Maxson WS, Vaughn WK, et al. Antiestrogenic effect of clomiphene citrate in a multiple follicular stimulation protocol. J In Vitro Fert Embryo Transf. 1986;3(2):106–9.
29. Fasouliotis SJ, Simon A, Laufer N. Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet. J Assist Reprod Genet. 2000;17(7):357–73.
30. Birkenfeld A, Mor-Joseph S, Ezra J, et al. Preovulatory luteinization during induction of follicular maturation with menotrophin and menotrophin-clomiphene combination. Hum Reprod. 1990;5(5):561–4.
31. World Health Organization. Temporal relations between ovulation and defined changes in the concentration of plasma estradiol-17 beta, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. WHO Task Force on Methods for the Determination of the Fertile Period. Am J Obstet Gynecol. 1980;138:383–90.
32. Collins W, Jurkovic D, Bourne T, et al. Ovarian morphology, endocrine function and intra-follicular blood flow during the peri-ovulatory period. Hum Reprod. 1991;6(3):319–24.
33. Yen SCC. The human menstrual cycle: neuroendocrine regulation. In: Yen SCC, Jaffe RB (Eds.). Reproductive Endocrinology, 3rd edition. Philadelphia, PA: WB Saunders; 1991. p 273–308.
34. In vitro fertilization-embryo transfer (IVF-ET) in the United States: 1990 results from the IVF-ET registry. Medical Research International. Society for Assisted Reproductive Technology (SART), The American Fertility Society. Fertil Steril. 1992(57):15–24.
35. Kim LH, Taylor AE, Barbieri RL. Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility? Fertil Steril. 2000;73(6):1097–8.
36. Johnson N. Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome - a meta-analysis of randomised trials. Aust N Z J Obstet Gynaecol. 2011;51(2):125–9.
37. Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2009(2):CD006105.
38. Swanton A, Lighten A, Granne I, et al. Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. Hum Reprod. 2011;26(8):2178–84.
39. Palomba S, Falbo A, Carrillo L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril. 2011;96(6):1384–90.
40. Jones GS. Update on in vitro fertilization. Endocr Rev. 1984;5(1):62–75.
41. Haning RV Jr, Levin RM, Behrman HR, et al. Plasma estradiol window and urinary estriol glucuronide determinations for monitoring menotropin induction of ovulation. Obstet Gynecol. 1979;54(4):442–7.
42. Seibel MM, McArdle CR, Thompson IE, Berger MJ, Taymor ML. The role of ultrasound in ovulation induction: a critical appraisal. Fertil Steril. 1981;36(5):573–7.
43. Navot D, Margalioth EJ, Laufer N, et al. Periovulatory 17 beta-estradiol pattern in conceptional and nonconceptional cycles during menotropin treatment of anovulatory infertility. Fertil Steril. 1987;47(2):234–7.
44. Shapiro SS. Clinical parameters influencing success in IVF. In: Wolf DP (Ed.). In Vitro Fertilization and Embryo Transfer, a Manual of Basic Techniques. New York: Plenum Press; 1988. p 397–8.
45. Hershlag A, Asis MC, Diamond MP, et al. The predictive value and the management of cycles with low initial estradiol levels. Fertil Steril. 1990;53(6):1064–7.
46. Laufer N, DeCherney AH, Tarlatzis BC, et al. The association between preovulatory serum 17 beta-estradiol pattern and conception in human menopausal gonadotropin-human chorionic gonadotropin stimulation. Fertil Steril. 1986;46(1):73–6.
47. Jones HW Jr, Acosta A, Andrews MC, et al. The importance of the follicular phase to success and failure in in vitro fertilization. Fertil Steril. 1983;40(3):317–21.
48. Penzias AS, Shamma FN, Gutmann JN, et al. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles. J Assist Reprod Genet. 1992;9(3):244–7.
49. Fleischer AC, Herbert CM, Sacks GA, et al. Sonography of the endometrium during conception and nonconception cycles of in vitro fertilization and embryo transfer. Fertil Steril. 1986;46(3):442–7.
50. Gonen Y, Casper RF, Jacobson W, et al. Endometrial thickness and growth during ovarian stimulation: a possible predictor of implantation in in vitro fertilization. Fertil Steril. 1989;52(3):446–50.
51. Rabinowitz R, Laufer N, Lewin A, et al. The value of ultrasonographic endometrial measurement in the prediction of pregnancy following in vitro fertilization. Fertil Steril. 1986;45(6):824–8.
52. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58(2):249–61.
53. Garcia-Velasco JA, Isaza V, Quea G, et al. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil Steril. 2006;85(3):547–54.
54. Delvigne A, Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update. 2002;8(3):291–6.
55. Moreno L, Diaz I, Pacheco A, et al. Extended coasting duration exerts a negative impact on IVF cycle outcome due to premature luteinization. Reprod Biomed Online. 2004;9(5):500–4.
56. Queenan JT Jr. Embryo freezing to prevent ovarian hyperstimulation syndrome. Mol Cell Endocrinol. 2000;169(1–2):79–83.
57. Manzanares MA, Gomez-Palomares JL, Ricciarelli E, et al. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril. 2010;93(4):1215–19.
58. Gonen Y, Balakier H, Powell W, et al. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990;71(4):918–22.
59. Bodri D, Guillen JJ, Galindo A, et al. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91(2):365–71.
60. McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994;344(8917):235–6.
61. Lesterhuis WJ, Rennings AJ, Leenders WP, et al. Vascular endothelial growth factor in systemic capillary leak syndrome. Am J Med. 2009;122(6):e5–7.
62. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20(5):1213–20.
63. Griesinger G, Diedrich K, Devroey P, et al. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12(2):159–68.
64. Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91.
65. Humaidan P, Kol S, Papanikolaou EG. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17(4):510–24.
66. Devroey P, Pellicer A, Nyboe Andersen A, Arce JC; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer (MEGASET) Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97:561–71.
67. Out HJ, Bennink HJ, de Laat WN. What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon): a scientific business. Hum Reprod. 1999;14(9):2189–90.
68. Group RHFs. Clinical assessment of recombinant human follicle stimulating hormone in stimulating ovarian follicle developement before in vitro fertilization. Fertil Steril. 1995;63:77–86.
69. Matorras R, Osuna C, Exposito A, et al. Recombinant FSH versus highly purified FSH in intrauterine insemination: systematic review and metaanalysis. Fertil Steril. 2011;95(6):1937–42, 1942.e1–3.
70. van Wely M, Kwan I, Burt AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;2:CD005354.
71. Laufer N, Simon A, Hurwitz A, et al. In vitro fertilization. In: Seibel MM (Ed.). Infertility: a Comprehensive Text. Stamford, CT: Appelton & Lange; 1996, p 703–49.
72. Porter RN, Smith W, Craft IL, et al. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet. 1984;2(8414):1284–5.
73. Pellicer A, Simon C, Miro F, et al. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod. 1989;4(3):285–9.
74. Rosen GF, Cassidenti DL, Stone SC, et al. Comparing mid-luteal and early follicular phase down regulation with Leuprolide acetate. In: 40th Annual Meeting of the Pacific Coast Fertility Society; 1992 April 8–12; Indian Wells, CA; 1992. (abstract P-19).
75. Seifer DB, Thornton KL, DeCherney AH, et al. Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success. Fertil Steril. 1991;56(3):500–4.
76. Howles CM, Macnamee MC, Edwards RG. Short term use of an LHRH agonist to treat poor responders entering an in-vitro fertilization programme. Hum Reprod. 1987;2(8):655–6.
77. Owen EJ, Davies MC, Kingsland CR, et al. The use of a short regimen of buserelin, a gonadotrophin-releasing hormone agonist, and human menopausal gonadotrophin in assisted conception cycles. Hum Reprod. 1989;4(7):749–53.
78. Matthews CD, Warnes GM, Norman RJ, et al. The leuprolide flare regime for in-vitro fertilization/gamete intra-fallopian transfer and embryo cryopreservation. Hum Reprod. 1991;6(6):817–22.
79. Acharya U, Small J, Randall J, et al. Prospective study of short and long regimens of gonadotropin-releasing hormone agonist in in vitro fertilization program. Fertil Steril. 1992;57(4):815–18.
80. Tan SL, Kingsland C, Campbell S, et al. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil Steril. 1992;57(4):810–14.
81. Martikainen H, Ronnberg L, Tapanainen J, et al. Endocrine responses to gonadotrophins after LHRH agonist administration on cycle days 1–4: prevention of premature luteinization. Hum Reprod. 1990;5(3):246–9.
82. Macnamee MC, Howles CM, Edwards RG, et al. Short-term luteinizing hormone-releasing hormone agonist treatment: prospective trial of a novel ovarian stimulation regimen for in vitro fertilization. Fertil Steril. 1989;52(2):264–9.
83. Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor. Hum Reprod. 2000;15(9):1882–3.
84. Felberbaum R, Diedrich K. Use of GnRH antagonists in ovulation induction. In: Filicori M, Flamigni C (Eds.). Treatment of Infertility: The New Frontiers. New Jersey: Communications Media for Education; 1998, p 135–8.
85. Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;(5):CD001750.
86. Griesinger G, Shapiro DB. Luteinizing hormone add-back: is it needed in controlled ovarian stimulation, and if so, when? J Reprod Med. 2011;56(7–8):279–300.
87. Sheikholislam BM, Stempfel RS Jr. Hereditary isolated somatotropin deficiency: effects of human growth hormone administration. Pediatrics. 1972;49(3):362–74.
88. Adashi EY, Resnik, CE, Hernandez ER, et al. Potential relevance of insulin-like growth factor I to ovarian physiology: from basic science to clinical application. Semin Reprod Endocrinol. 1989;7:94–9.
89. Adashi EY, Resnick CE, D’Ercole AJ, et al. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev. 1985;6(3):400–20.
90. Adashi EY, Resnick CE, Svoboda ME, et al. Follicle-stimulating hormone enhances somatomedin C binding to cultured rat granulosa cells. Evidence for cAMP dependence. J Biol Chem. 1986;261(9):3923–6.
91. Adashi EY, Resnick CE, Svoboda ME, et al. Somatomedin-C synergizes with follicle-stimulating hormone in the acquisition of progestin biosynthetic capacity by cultured rat granulosa cells. Endocrinology. 1985;116(6):2135–42.
92. Jia XC, Kalmijn J, Hsueh AJ. Growth hormone enhances follicle-stimulating hormone-induced differentiation of cultured rat granulosa cells. Endocrinology. 1986;118(4):1401–9.
93. Erickson GF, Garzo VG, Magoffin DA. Insulin-like growth factor-I regulates aromatase activity in human granulosa and granulosa luteal cells. J Clin Endocrinol Metab. 1989;69(4):716–24.
94. Mason HD, Martikainen H, Beard RW, et al. Direct gonadotrophic effect of growth hormone on oestradiol production by human granulosa cells in vitro. J Endocrinol. 1990;126(3):R1–4.
95. Homburg R, Eshel A, Abdalla HI, Jacobs HS. Growth hormone facilitates ovulation induction by gonadotrophins. Clin Endocrinol (Oxf). 1988;29(1):113–17.
96. Owen EJ, West C, Torresani T, et al. Insulin-like-growth factors in women receiving growth hormone on addition to clomophene and human menopausal gonadotropines for IVF-ET. In: 6th World Congress of In Vitro Fertilization and Alternate Assisted Reproduction; 1989 April 2–7; Jerusalem, Israel; 1989, p 28.
97. Volpe A, Coukos G, Barreca A, et al. Ovarian response to combined growth hormone-gonadotropin treatment in patients resistant to induction of superovulation. Gynecol Endocrinol. 1989;3(2):125–33.
98. Menashe Y, Lunenfeld B, Pariente C, et al. Effect of growth hormone on ovarian responsiveness II. In: Joint meeting of the European Society of Human Reproduction and Embryology; 1990 August 29; Milan, Italy; 1990. (abstract 190).
99. Kolibianakis EM, Venetis CA, Diedrich K, et al. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2009;15(6):613–22.
100. Duffy JM, Ahmad G, Mohiyiddeen L, et al. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev. 2010;(1):CD000099.
101. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011;9:67.
102. Wiser A, Gonen O, Ghetler Y, et al. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod. 2010;25(10):2496–500.
Cancel
Confirm
×